The FDA hand­ed a CRL to the Swedish biotech Ca­mu­rus for its hor­mone dis­or­der ther­a­py over “fa­cil­i­ty-re­lat­ed de­fi­cien­cies” at a third-par­ty man­u­fac­tur­er.

Fintel reports that on October 23, 2024, CLSA initiated coverage of Charles River Laboratories International (NYSE:CRL) with a Underperform recommendation. As of October 22, 2024, the average one ...